Axsome TherapeuticsAXSM
AXSM
About: Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Employees: 589
0
Funds holding %
of 6,790 funds
0
Analysts bullish %
of 12 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
77% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 26
8% more funds holding
Funds holding: 254 [Q2] → 274 (+20) [Q3]
4% more capital invested
Capital invested by funds: $3.3B [Q2] → $3.43B (+$132M) [Q3]
2% more call options, than puts
Call options by funds: $95.7M | Put options by funds: $94M
5.95% less ownership
Funds ownership: 86.44% [Q2] → 80.49% (-5.95%) [Q3]
13% less repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 93
27% less funds holding in top 10
Funds holding in top 10: 11 [Q2] → 8 (-3) [Q3]
Research analyst outlook
12 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$107
7%
upside
Avg. target
$134
34%
upside
High target
$180
81%
upside
12 analyst ratings
12 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Raghuram Selvaraju 41% 1-year accuracy 86 / 210 met price target | 81%upside $180 | Buy Reiterated | 27 Nov 2024 |
HC Wainwright & Co. Raghuram Selvaraju 41% 1-year accuracy 86 / 210 met price target | 81%upside $180 | Buy Reiterated | 25 Nov 2024 |
Baird Joel Beatty 59% 1-year accuracy 17 / 29 met price target | 17%upside $116 | Outperform Maintained | 13 Nov 2024 |
Needham Ami Fadia 54% 1-year accuracy 75 / 138 met price target | 31%upside $130 | Buy Reiterated | 13 Nov 2024 |
Needham Ami Fadia 54% 1-year accuracy 75 / 138 met price target | 31%upside $130 | Buy Reiterated | 12 Nov 2024 |
Financial journalist opinion
Based on 9 articles about AXSM published over the past 30 days
Positive
Seeking Alpha
5 days ago
Axsome: Focus On AXS-12 Targeting Narcolepsy, Which Just Released Positive Data
Axsome's AXS-12 met its primary endpoint in a Phase 3 study, significantly reducing cataplexy attacks in narcolepsy patients, positioning it for an NDA submission. The narcolepsy market is substantial, with current treatments having issues like tolerability and efficacy, which AXS-12 aims to address effectively. Financially, Axsome has a market cap of $4.83bn, strong revenue growth, but a net loss, indicating a cash runway of four to five quarters.
Positive
Benzinga
1 week ago
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says
On Tuesday, Axsome Therapeutics Inc AXSM said AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) in Phase 3 ENCORE trial.
Positive
Zacks Investment Research
3 weeks ago
Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up
AXSM posts better-than-expected third-quarter results. Stock rises in response to the results and strong sales uptake of Auvelity.
Neutral
Seeking Alpha
3 weeks ago
Axsome Therapeutics, Inc. (AXSM) Q3 2024 Earnings Call Transcript
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick Pizzie - CFO Ari Maizel - EVP and Head, Commercial Mark Jacobson - Chief Operating Officer Conference Call Participants Jason Gerberry - Bank of America Leonid Timashev - RBC Capital Markets Charles Duncan - Cantor Fitzgerald Cerena Chen - Wells Fargo David Amsellem - Piper Sandler Marc Goodman - Leerink Partners Joseph Thome - TD Cowen Myles Minter - William Blair Poorna Kannan - Needham & Company Joel Beatty - Baird Graig Suvannavejh - Mizuho Securities Matt Kaplan - Ladenburg Thalmann Operator Good morning, and welcome to the Axsome Therapeutics Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Positive
Seeking Alpha
3 weeks ago
Axsome Therapeutics Q3 Earnings: Stay For The Near Term Catalysts, Then Sell
Axsome Therapeutics' Q3 2024 earnings report shows a revenue beat with $104.8m, up 81% YoY, but net loss increased to $(64.6m). Despite positive market response and promising pipeline candidates, Axsome's profitability remains distant, with significant cash burn and competition from pharma giants. AXS-07 is likely to gain FDA approval in January for migraine treatment, while AXS-05 shows potential for Alzheimer's agitation, but “blockbuster” revenue status is uncertain.
Negative
Zacks Investment Research
3 weeks ago
Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates
Axsome Therapeutics (AXSM) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of $1.38. This compares to loss of $1.32 per share a year ago.
Positive
Zacks Investment Research
3 weeks ago
Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?
Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 results this week.
Neutral
GlobeNewsWire
3 weeks ago
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024
NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced eight presentations spanning its innovative portfolio of late-stage products and product candidates in psychiatry and neurology at NEI Congress 2024, being held Nov. 7 - Nov. 10, 2024, in Colorado Springs, Colorado.
Negative
Zacks Investment Research
4 weeks ago
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
1 month ago
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced seven presentations from across its broad portfolio of innovative neuroscience products and product candidates at Psych Congress 2024, being held Oct. 29 - Nov. 2, 2024, in Boston, Massachusetts.
Charts implemented using Lightweight Charts™